Skip to content

Study of NK Combined With Chemotherapy for Advanced Solid Tumor

Study of Natural Killer Cell Combined With Chemotherapy for Advanced Solid Tumor

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04214730
Acronym
NK
Enrollment
60
Registered
2020-01-02
Start date
2019-12-31
Completion date
2023-12-31
Last updated
2023-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumor

Brief summary

Combinations Natural Killer Cell (NK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.

Detailed description

Patients in group A will receive 4 cycles of NK treatments within 8 months. Patients in group B will have no immunotherapy. Chemotherapy are available in both groups.The investigators want to evaluate the efficacy of combination of NK with chemotherapy in patients with treatment-refractory solid tumors

Interventions

COMBINATION_PRODUCTNK combined with Chemotherapy

Patients will receive 4 cycles of NK treatments combined with Chemotherapy within 8 months

DRUGChemotherapy

Patients will only receive Chemotherapy.

Sponsors

Yantai Yuhuangding Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
10 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Patients with treatment-refractory advanced solid cancer can not accept operation; 2. Age 10 to 90 years; 3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points; 4. estimate survival \> 3 months; 5. Blood White Blood Cell(WBC)≥ 4×109/L, Hb ≥ 100g/L, Platelet Count (PLT)≥ 80×109/L; Alanine amino transferase (ALT) and aspartate amino transferase (AST)≤ 2 times of normal upper value; Serum Cr ≤ 2 normal upper value; 6. Without any other malignant disease; 7. With more than one scalable lesions; 8. Patients Voluntary attempt, and informed consent; 9. Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus.

Exclusion criteria

1. Patients who do not conform to the inclusion criteria; 2. Patients with uncontrolled infection; underlying disease that was severe or life-threatening (such as uncontrolled brain metastasis ); 3. Patients who were pregnant or lactating; 4. ECOG perform status ≥ 2;4. 5. Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, etc.)

Design outcomes

Primary

MeasureTime frameDescription
Disease Control Rates (DCR)1 yearDisease Control Rates (Complete Remission + Partial Remission + Stable Disease), according to solid tumor response evaluation standard (response evaluation criteria in solid tumors, RECIST).

Countries

China

Contacts

Primary ContactPeiwen Lian, PhD
peiwen.lian@hotmail.com+0086 5356691999
Backup ContactJian Chen, PhD
chenjianyt@163.com+0086 5356691999

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026